Product Details
Daptomycin for Injection
Daptomycin500 mg/Vial
Powder for Solution for Injection
Vial Pack
DIN/PIN/NPN
02490463
Manufacturer
Dr. Reddy's Laboratories Inc.
Formulary Listing Date
2020-11-30
Unit Price
162.3500
Amount MOH Pays
162.3500
Coverage Status
Off-Formulary Interchangeable Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
J01XX09
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02490838 | Daptomycin for Injection | 162.3500 | 162.3500 |
02490463 | Daptomycin for Injection | 162.3500 | 162.3500 |
02299909 | Cubicin | NA | NA |
02511738 | Daptomycin for Injection | 162.3500 | 162.3500 |
LU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Anti-Infectives | Daptomycin
Note that initial requests for Daptomycin may be accessed through the EAP’s Telephone Request Service for some of the below indications (see latter part of this document under TRS). For the treatment of patients experiencing the following types of infections due to methicillin-resistant Staphylococcus aureus (MRSA) bacteria:
Additionally, the patient must have failed to adequately respond to, be intolerant1 to, or have a contraindication to vancomycin. 1Intolerance due to Red Man Syndrome. If the physician asserts that the patient is intolerant to vancomycin due to red man’s syndrome, additional clinical details of the patient’s intolerance, including rate of infusion and the use of antihistamines and other histamine blockers prior to therapy with vancomycin. Duration of Approval: Up to 8 weeks Renewals will be considered on a case-by-case basis. (Physicians must submit adequate clinical information to justify the need for ongoing therapy with daptomycin.) Duration of Approval: Case-by-case Exclusion Criteria:
For the treatment of invasive infections1 caused by vancomycin-resistant enterococcus (VRE) in patients who meet the following criteria:
1Not approved for colonization (e.g., nares, skin, stool) 2Intolerances and contraindications to linezolid must be fully described in the EAP application. Recommended dose: 8 to 12 mg/kg daily for VRE with adjustments based on renal function Duration of approval:
Requests for longer durations of funding will be considered case-by-case through external review and must be accompanied by a recent microbiology sensitivity report to confirm sensitivity to daptomycin. EAP Drug Request Form: |
Anti-Infectives – Telephone Request Service (TRS) Drugs | Daptomycin
For the treatment of patients with one or more of the following condition(s):
Additionally, the patient must have failed to adequately respond to, be intolerant* to, or have a contraindication to vancomycin. *Requests involving red-man-syndrome with vancomycin must provide details of the intolerance including the rate of infusion and the use of antihistamines and other histamine blockers prior to therapy. Standard Approval Duration: Up to maximum of 56 days Exclusion Criteria: Daptomycin is not funded for patients with:
For the treatment of invasive infections1 caused by vancomycin-resistant enterococcus (VRE) in patients who meet the following criteria:
1Not approved for colonization (e.g., nares, skin, stool) 2Intolerances and contraindications to linezolid must be fully described in the EAP application. Recommended dose: 8 to 12 mg/kg daily for VRE with adjustments based on renal function Duration of approval: Note that the below are examples of durations for reimbursement of some common VRE infections. This is not an all-inclusive list.
Requests for longer durations of funding will be considered case-by-case through external review and must be accompanied by a recent microbiology sensitivity report to confirm sensitivity to daptomycin. |